On Jan. 3, 2017, the U.S. Food and Drug Administration’s Center for Veterinary Medicine (CVM) announced the conditional approval of Tanovea-CA1 (rabacfosadine for injection), the first new animal drug intended to treat canine lymphoma.

The drug was developed by Fort Collins-based VetDC in cooperation with the Colorado State University. Tanovea was discovered by Gilead Sciences, and was originally designed to treat lymphoma in human patients.